Biomaterials to study tolerance immune induction kinetics
Biomaterials to study tolerance immune induction kinetics
批准号:
9979740
负责人:
Kristy M Ainslie
金额:
$37.66万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-14 至 2023-07-31
关键词:
AbbreviationsAcetalsAcidsAddressAdoptive TransferAffectAftercareAmericanAnimal ModelAnti-Inflammatory AgentsAntibodiesAntigen PresentationAntigen-Presenting CellsAntigensAutoimmune DiseasesAutoimmune ProcessBiocompatible MaterialsBiological ModelsC57BL/6 MouseCD80 geneCardiotoxicityCell CommunicationCell physiologyCellsClinicalCohort EffectCommunicationDataDelayed HypersensitivityDendritic CellsDevelopmentDexamethasoneDextransDiseaseDoseEncapsulatedEngineeringEvaluationExperimental Autoimmune EncephalomyelitisExperimental ModelsFOXP3 geneFormulationGenerationsGlycolatesGoalsHepatotoxicityHourIL2RA geneITGAM geneITGAX geneImmuneImmune ToleranceImmunologicsImmunologistImmunosuppressionIn VitroInfectionInflammationInterferon Type IIInterferonsInterleukin-10KineticsLipopolysaccharidesMajor Histocompatibility ComplexMalignant NeoplasmsMeasuresMediatingMethodsModelingMolecular Sieve ChromatographyMultiple SclerosisMusMyelin Basic ProteinsOnset of illnessOvalbuminParticle SizeParticulatePathogenesisPeptidesPeriodicityPhagocytesPhagolysosomePhagosomesPharmaceutical PreparationsPolyestersPolymersProteinsProteolipidsPublishingReadingRegulatory T-LymphocyteRelapseResearchResearch PersonnelRiskRoleSignal TransductionSirolimusSpleenSplenocyteSystemT cell responseT-LymphocyteT-Lymphocyte SubsetsTechnologyTimeTransforming Growth FactorsVaccinesWorkattenuationbiodegradable polymercentral nervous system demyelinating disorderclinically relevantcytokinedesigneffector T cellexperimental studyimmunological synapsein vivomacrophagemouse modelmultiple sclerosis treatmentnanonanoparticleoligodendrocyte-myelin glycoproteinparticleresponseside effect
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT
We plan to explore the kinetics of the immune synapse, as it relates to generation of tolerance, using
nano/microparticles (Ps) fabricated from the polymer acetalated dextran (Ac-DEX). Previously, we have shown
attenuation of clinical score with treatment of Ac-DEX particles encapsulating myelin basic protein (MBP) and
dexamethasone (DXM), using a C57Bl/6 mouse model of experimental autoimmune encephalomyelitis (EAE).
We continued this research and illustrated that Ac-DEX particles encapsulating proteolipid protein (PLP) and
rapamycin (Rapa) in a SJL relapse and remitting model of EAE completely reduced clinical score to baseline
when given after disease onset. The degree of reduction of clinical score for both of these EAE models was
greater for the Ac-DEX particles systems than observed in other published antigen-specific EAE treatments that
used particle systems. Our particle system is unique because it relies on the highly tunable polymer Ac-DEX.
Ac-DEX is ideal for delivery of agents to phagocytic cells because it is acid-sensitive and has significantly
increased degradation in the low acid (~pH 5) of the phagosome. In addition to this it has tunable degradation
rates that can range from hours to months, which is a unique range from commonly used polyesters (e.g.
poly(lactic-co-glycolic acid) (PLGA)) that have degradation on the order of months. Moreover, Ac-DEX is unique
from polyesters because its degradation products are pH neutral, and do not have the potential to shift the local
pH or damage sensitive payloads. We have shown that Ac-DEX particles have degradation rates that affect both
antibody and cellular response for traditional vaccine and hypothesize similar effects for generation of tolerance.
Therefore, we hypothesize that Ac-DEX particles promote antigen specific immune tolerance by inducing Tregs
and that the cyclic acetal coverage of Ac-DEX impact degradation rate and modulate the immune synapse. We
have three specific aims to address this hypothesis. Aim 1 is focused on formulation of the polymer and particles.
Both a MS representative antigen as well as the model antigen OVA will be encapsulated. Particle parameters
like size and loading will be determined. Ac-DEX polymer with various cyclic acetal coverages will be fabricated
to degrade over a broad range of times. Aim 2 focuses on in vitro and in vivo studies to understand the immune
synapse and how that relates to particle degradation times. The metrics for evaluation will be generation of
inducible T-regulatory cells (iTregs). Furthermore, we will optimize systems using a delayed type hypersensitivity
(DTH) model of inflammation. The relationship between particle degradation and generation of tolerance will be
optimized. In Aim 3, the optimized formulation will be evaluated in a model of MS and expression of Tregs, as well
as other immunological characterizations will be carried out. The overall goal of this work is to evaluate the Ac-
DEX particles systems as an antigen-specific treatment for MS and to understand the influence of release of
tolerance agents (e.g. antigen and Rapa) on the generation of antigen specific immune tolerance.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanistic evaluation of mast cell agonists combined with TLR, NOD and STING agonists.
-
批准号:10657847
-
项目类别:
-
资助金额:$64.52万
-
财政年份:2023
-
负责人:Kristy M Ainslie
-
依托单位:
Diversity Supplement - Formulation to Generate Tolerance Towards Type 1 Diabetes
-
批准号:10560761
-
项目类别:
-
资助金额:$11.01万
-
财政年份:2021
-
负责人:Kristy M Ainslie
-
依托单位:
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
-
批准号:10449370
-
项目类别:
-
资助金额:$34.91万
-
财政年份:2021
-
负责人:Kristy M Ainslie
-
依托单位:
Formulation to Generate Tolerance Towards Type 1 Diabetes
-
批准号:10436981
-
项目类别:
-
资助金额:$38.18万
-
财政年份:2021
-
负责人:Kristy M Ainslie
-
依托单位:
Formulation to Generate Tolerance Towards Type 1 Diabetes
-
批准号:10713401
-
项目类别:
-
资助金额:$11.08万
-
财政年份:2021
-
负责人:Kristy M Ainslie
-
依托单位:
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
-
批准号:10675073
-
项目类别:
-
资助金额:$34.3万
-
财政年份:2021
-
负责人:Kristy M Ainslie
-
依托单位:
Formulation to Generate Tolerance Towards Type 1 Diabetes
-
批准号:10310642
-
项目类别:
-
资助金额:$38.2万
-
财政年份:2021
-
负责人:Kristy M Ainslie
-
依托单位:
Formulation to Generate Tolerance Towards Type 1 Diabetes
-
批准号:10615119
-
项目类别:
-
资助金额:$38.16万
-
财政年份:2021
-
负责人:Kristy M Ainslie
-
依托单位:
Tunable Temporal Drug Release for Optimized Synergistic Combination Therapy of Glioblastoma
-
批准号:10309049
-
项目类别:
-
资助金额:$35.64万
-
财政年份:2021
-
负责人:Kristy M Ainslie
-
依托单位:
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
-
批准号:10328236
-
项目类别:
-
资助金额:$56.87万
-
财政年份:2020
-
负责人:Kristy M Ainslie
-
依托单位:
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
-
批准号:10540741
-
项目类别:
-
资助金额:$56.04万
-
财政年份:2020
-
负责人:Kristy M Ainslie
-
依托单位:
Optimizing a Universal Influenza Subunit Nano/Microparticulate Vaccine
-
批准号:9916920
-
项目类别:
-
资助金额:$60.43万
-
财政年份:2020
-
负责人:Kristy M Ainslie
-
依托单位:
Biomaterials to study tolerance immune induction kinetics
-
批准号:10223121
-
项目类别:
-
资助金额:$37.66万
-
财政年份:2018
-
负责人:Kristy M Ainslie
-
依托单位:
Biomaterials to study tolerance immune induction kinetics
-
批准号:9763439
-
项目类别:
-
资助金额:$37.66万
-
财政年份:2018
-
负责人:Kristy M Ainslie
-
依托单位:
Biomaterials to study tolerance immune induction kinetics
-
批准号:10458635
-
项目类别:
-
资助金额:$37.66万
-
财政年份:2018
-
负责人:Kristy M Ainslie
-
依托单位:
Microparticle resiquimod for the treatment of visceral leishmaniasis
-
批准号:9259909
-
项目类别:
-
资助金额:$22.45万
-
财政年份:2016
-
负责人:Kristy M Ainslie
-
依托单位:
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection
-
批准号:9145977
-
项目类别:
-
资助金额:$140.68万
-
财政年份:2016
-
负责人:Kristy M Ainslie
-
依托单位:
Microparticle resiquimod for the treatment of visceral leishmaniasis
-
批准号:9091911
-
项目类别:
-
资助金额:$19.93万
-
财政年份:2016
-
负责人:Kristy M Ainslie
-
依托单位:
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection
-
批准号:9901429
-
项目类别:
-
资助金额:$104.34万
-
财政年份:2016
-
负责人:Kristy M Ainslie
-
依托单位:
Host Targeted Therapy for Drug Resistant Salmonella and Francisella infection
-
批准号:9265787
-
项目类别:
-
资助金额:$127.92万
-
财政年份:2016
-
负责人:Kristy M Ainslie
-
依托单位:
海外基金